

Diabetes Ther (2014) 5:323–332
DOI 10.1007/s13300-014-0050-6

CASE REPORT

Effects of Exenatide in a Morbidly Obese Patient with Type 2 Diabetes

Miyako Kishimoto · Mitsuhiro Noda

To view enhanced content go to www.diabetestherapy-open.com
Received: November 12, 2013 / Published online: January 18, 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

ABSTRACT

Introduction: The effect of exenatide in weight loss has been reported. Presented here is a case of a morbidly obese patient with type 2 diabetes using exenatide who dramatically lost her body weight in a year and experienced improved glycemic control.

Case report: Exenatide therapy was initiated for a 59-year-old morbidly obese Japanese

Electronic supplementary material The online version of this article (doi:[10.1007/s13300-014-0050-6](https://doi.org/10.1007/s13300-014-0050-6)) contains supplementary material, which is available to authorized users.

M. Kishimoto (✉)
Department of Diabetes, Endocrinology, and Metabolism, Center Hospital, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan
e-mail: mkishimo@hosp.ncgm.go.jp

M. Kishimoto · M. Noda
Diabetes and Metabolism Information Center, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

M. Noda
Department of Diabetes Research, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

woman with type 2 diabetes. To examine the effects of the exenatide treatment, continuous glucose monitoring was performed, and blood was drawn at 0, 30, 60, 120, and 180 min after breakfast to measure insulin, glucagon, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic peptide (GIP) levels. After 1 year of exenatide therapy, the patient lost 37.5 kg, her glycemic control improved, and her insulin sensitivity recovered. The patient's levels of insulin, glucagon, active GLP-1, and total GIP also decreased after 1 year of exenatide treatment.

Conclusion: The exenatide treatment was effective for reducing body weight and improving glycemic control. After 1 year of exenatide treatment, decreased glucagon, active GLP-1, and total GIP levels were observed following a meal, suggesting that exenatide might affect these hormonal reactions.

Keywords: Exenatide; Glucagon; Glucose-dependent insulinotropic peptide; Glucagon-like peptide-1; Insulin sensitivity; Type 2 diabetes mellitus

INTRODUCTION

Overweight and obesity are defined as abnormal or excessive fat accumulation that may impair health. The World Health Organization (WHO) estimates that at least 2.8 million adults die each year as a result of being overweight or obese and that 44% of the diabetes burden, 23% of the ischemic heart disease burden, and 7–41% of the burden associated with certain cancers are attributable to overweight and obesity [1].

Links between obesity and diabetes have been firmly established [2–4]. In obesity, visceral fat secretes adipocytokines such as tumor necrosis factor- α (TNF- α) [5] and resistin [6], resulting in insulin resistance, which then progresses to impaired insulin secretion. Weight reduction can attenuate the abnormal adipocytokine secretion and may improve insulin resistance and glucose metabolism [7]. Therefore, weight loss can be used as a therapeutic treatment for patients with obesity-induced diabetes; however, if the desired weight loss is not achievable, medication for diabetes management is necessary in addition to weight management.

Gut peptides, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulintropic polypeptide (GIP), are secreted in a nutrient-dependent manner and stimulate glucose-dependent insulin secretion [8, 9]. Exenatide, a GLP-1 analog, is a new class of antidiabetic drug that potentiates glucose-dependent insulin secretion, lowers serum glucagon levels, slows gastric emptying, and may promote weight loss by increasing satiety [10–13]. The effect of exenatide in weight loss has been reported, with considerable variation in the amount of weight that is lost [14–23].

This case report presents a case of a morbidly obese patient with type 2 diabetes using

exenatide who successfully lost 37.5 kg of body weight in a year and experienced improved glycemic control. To assess the efficacy of this drug, we also report hormonal changes in insulin, glucagon, GLP-1, and GIP levels before and after the exenatide treatment.

CASE REPORT

History of Obesity and Diabetes

A 59-year-old Japanese woman began experiencing weight gain at the age of 38 years due to overeating in response to mental stress. When she was 48 years old, she retired from work because of a disc herniation; as a result, she spent most of her time at home, decreased her physical activity, and gained additional weight. At the age of 49 years, her body weight reached 153 kg [height 156.2 cm, body mass index (BMI) 62.7 kg/m²]. Hormonal examinations revealed that she was unlikely to have endocrinological diseases such as Cushing's disease or hypothyroidism. Her HbA1c level was 8.8% at this time, and she was admitted to the hospital for obesity and glucose management. After 15 weeks in hospital with a dietary intake of 1,200 kcal per day, her weight was successfully reduced to 131.2 kg (BMI 53.9 kg/m²) and her HbA1c level also decreased to 6.5%. However, after discharge, she gradually regained weight to 163.0 kg (BMI 66.8 kg/m²) and her HbA1c level increased to 9.3%. Thereafter, she repeatedly gained and lost weight and required ongoing weight management support. In 2010, at the age of 55 years and a weight of 144.1 kg (BMI 59.1 kg/m²), she required a total dosage of 36 units of insulin by injection, and her glycemic control was poor (HbA1c 10.5%). However, as she gradually reduced her weight again to

121 kg (BMI 49.6 kg/m²), her total dosage of insulin also decreased to 28 units. Finally, at a body weight of 114 kg (BMI 46.7 kg/m²), she could maintain an HbA1c level of 6.6% without the use of medication, including insulin injections.

Previous weight management strategies included the use of the anti-obesity drug mazindol, a very low calorie diet (800 kcal/day), and counseling by a psychotherapist. Exercise therapy was restricted to the upper part of the body because of knee pain resulting from weight-induced osteoarthritis. While the aforementioned strategies were effective during a hospital admission, they did not result in long-term weight loss after discharge. Gastric surgery (e.g., sleeve gastrectomy) was also considered, but it was not performed due to her inability to cover the medical expense and the presence of renal dysfunction [eGFR, 21.8 mL/(min·1.73 m²)].

Administration of Exenatide

Following the patient's weight reduction in March 2011 to 112.1 kg (BMI 45.9 kg/m²), she regained her weight and more to reach 133.8 kg (BMI 54.8 kg/m²) in August 2012, and her HbA1c level was 8.2%. Therefore, exenatide therapy was commenced with 5 µg injected twice a day within the 60 min before the morning and evening meals. The goals of this therapy were glycemic control and weight loss. In August 2013, following 1 year of exenatide therapy, her weight was 96.3 kg (BMI 39.5 kg/m²).

Glucose metabolism was assessed at 3 occasions (March 2011, August 2012, and August 2013) with a continuous glucose monitoring system (CGMS) (CGMS[®]-GOLD[™]; Medtronic MiniMed, Northridge, CA, USA), and measurements of serum insulin and plasma glucagon were conducted using blood samples

that were drawn at 5 time points (0, 30, 60, 120, and 180 min) after breakfast following a 14-h overnight fast.

In addition, to assess the changes in incretin markers before the exenatide treatment, baseline active GLP-1 and total GIP levels were also measured at the 5 time points after breakfast in August 2012. To assess the effect of the exenatide treatment over 1 year, a washout period (5 days without exenatide) was conducted prior to the assessment in August 2013, and active GLP-1 and total GIP levels were measured at the same 5 time points after breakfast. Blood samples for the determination of active GLP-1 and total GIP levels were collected into BD[™] P800 tubes (Becton-Dickinson, Franklin Lakes, NJ, USA) containing spray-dried K₂EDTA anticoagulant and a proprietary cocktail of protease, esterase, and dipeptidyl peptidase 4 (DPP-4) inhibitors. The area under the curve (AUC) values for continuous glucose monitoring (CGM) measured glucose, insulin, glucagon, active GLP-1 and total GIP levels, after meal ingestion, were calculated using the trapezoidal rule.

For all occasions, total caloric intake was maintained at 1,600 kcal per day (breakfast 365–410 kcal). To assess the minimum amount of energy required by the patient, her resting metabolic rate (RMR) was measured using a FitMate metabolic system (Cosmed, Rome, Italy).

Finally, to evaluate the levels of insulin resistance and insulin secretion in this patient, the homeostasis model assessment of insulin resistance (HOMA-IR) and the homeostasis model assessment of β cell function (HOMA-β) were done [24, 25]. In addition, the quantitative insulin-sensitivity check index (QUICKI) was calculated using the standard formula: 1/[log (glucose) + log (insulin)] [26].

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from the patient for being included in the study.

RESULTS

During the periods of exenatide administration, the patient experienced mild gastrointestinal symptoms such as nausea and appetite loss; however, these adverse effects were not serious enough to cease the exenatide therapy. Changes in body weight, BMI, HbA1c levels, RMR, HOMA-IR, HOMA- β , and QUICKI at the 3 measurement points (March 2011, August 2012, and August 2013) are shown in Table 1. As weight was lost, the RMI and HOMA-IR reduced while QUICKI values increased. The value of HOMA- β decreased in August 2012

Table 1 Anthropometric and glucose metabolism parameters at 3 time points

Parameter	2011 Mar	2012 Aug ^a	2013 Aug
Body weight (kg)	112.1	133.8	96.3
BMI (kg/m ²)	45.9	54.8	39.5
HbA1c (%)	6.0	8.2	5.1
RMR (kcal/day)	1,732	2,331	1,618
HOMA-IR	1.08	4.89	1.29
HOMA- β (%)	95.4	55.7	57.2
QUICKI	0.201	0.082	0.195

BMI body mass index, *RMR* resting metabolic rate, *HOMA-IR* homeostasis model assessment ratio, *HOMA- β* homeostasis model assessment β cell function, *QUICKI* quantitative insulin-sensitivity check index

^a Exenatide treatment commenced (5 μ g injected twice a day within the 60 min before the morning and evening meals) and continued until August 2013

after the weight gain and did not change following the weight loss in August 2013.

Figure 1 shows the fluctuations in glucose levels measured by CGM. The average \pm standard deviation (SD) of the CGM measurements for each of the three occasions (March 2011, August 2012, and August 2013) was 119.7 ± 7 , 197 ± 16 , and 117 ± 7 mg/dL, respectively, reflecting the attenuation of glucose fluctuations with weight loss.

Time-dependent changes in serum insulin, plasma glucagon, active GLP-1, and total GIP levels are shown in Fig. 2. The AUC values of these hormones up to 3 h after the meal ingestion are summarized in Table 2. Compared to August 2012, the insulin levels and insulin AUC values were lower at each measurement in March 2011 and August 2013 (Fig. 2a). Glucagon levels and glucagon AUC values at each measurement were lower in August 2013 compared to those in March 2011 and August 2012 (Fig. 2b). The active GLP-1 and total GIP levels decreased at all of the measurement points in August 2013 compared to those in August 2012 (Fig. 2c, d).

DISCUSSION

Although substantial lifestyle changes, such as an increase in physical activity and dietary modifications, are essential and effective for obesity management; low compliance results in a need for pharmacological or surgical intervention in some cases. For the patient in this report, dietary modifications, exercise, and a pharmacological intervention were not effective, and surgical intervention was not an option. However, the use of exenatide contributed to a 37.5 kg weight loss and improved glycemic control in the patient. This improvement in glycemic control was related to both the weight loss and exenatide therapy;




Fig. 1 The results of continuous glucose monitoring (CGM) in a morbidly obese female patient with type 2 diabetes in March 2011 (a), August 2012 (b), and August 2013 (c). Exenatide treatment commenced (5 µg injected twice a day within the 60 min before the morning and

evening meals) in August 2012 and continued until August 2013. *Marks on the lines* indicate a calibration of the CGM system, and the *marks at the bottom* of the figures indicate the three meals




Fig. 2 Time course of insulin (a), glucagon (b), active glucagon-like peptide-1 (GLP-1) (c), and total glucose-dependent insulinotropic polypeptide (GIP) (d) levels before and after food intake in a morbidly obese female patient with type 2 diabetes. The *filled squares* indicate results in March

2011, the *filled triangles* indicate the results in August 2012, and the *clear triangles* indicate the results in August 2013. Exenatide treatment commenced (5 µg injected twice a day within the 60 min before the morning and evening meals) in August 2012 and continued until August 2013

Table 2 Area under the curve (AUC) values for the 3 h after breakfast

Parameter	2011	2012	2013
	Mar	Aug ^a	Aug
Glucose (CGM) ($10^3 \times \text{mg/dL} \cdot 3 \text{ h}$)	23.4	34.9	21.4
Insulin ($10^3 \times \text{pmol/L} \cdot 3 \text{ h}$)	12.7	24.6	12.2
Glucagon ($10^3 \times \text{ng/L} \cdot 3 \text{ h}$)	18.2	15.5	13.0
GLP-1 (active) ($10^2 \times \text{pmol/L} \cdot 3 \text{ h}$)	N/A	3.7	2.9
GIP (total) ($10^3 \times \text{pmol/L} \cdot 3 \text{ h}$)	N/A	15.1	8.9

CGM continuous glucose monitoring, GIP glucose-dependent insulinotropic polypeptide, GLP-1 glucagon-like peptide-1, N/A not available

^a Exenatide treatment commenced (5 μg injected twice a day within the 60 min before the morning and evening meals) and continued until August 2013

however, the exenatide injections were ceased for the 5 days before the assessment in Aug 2013. Therefore, weight loss is likely to be the primary reason for the observed changes.

The fluctuations in the post-prandial insulin levels displayed in the patient were related to the changes in her weight; when her weight was higher (133.8 kg), the insulin levels increased, and when her weight was lower (112.1 and 96.3 kg), the insulin levels decreased. This relationship indicated that the level of insulin resistance decreased, and the hyperinsulinemia was ameliorated.

Glucagon levels decreased after 1 year of exenatide therapy, despite the decrease in glucose levels. Although GLP-1 is a powerful suppressor of glucagon secretion, a decrease in glucose levels should result in increased glucagon secretion. The balance of these phenomena may lead to a decrease in glucagon secretion. Secretion of GLP-1 is generally impaired in obesity [27] resulting in a reduction in the circulating GLP-1 levels in obese patients [10, 28, 29]. Moreover, the GLP-1 response to oral stimulation has been negatively

correlated with BMI [27, 29], and weight loss is associated with an increased GLP-1 response to meal ingestion [28]. However, in this case report, the patient's GLP-1 levels were reduced at all of the post-prandial measurements following the exenatide treatment. This may be due to the decreased glucose levels because GLP-1 is secreted in a glucose-dependent manner. In addition, the effect of exenatide on gastric emptying or the inhibitory feedback for GLP-1 secretion may explain the reduction in GLP-1 levels [14, 30]. The post-prandial total GIP levels were also decreased in the patient following exenatide therapy. The potential reason for this is unclear, but it might be attributed to the reduction in glucose levels. Measurements of active GIP in future studies may provide more insight into this relationship.

Islet β cell failure in type 2 diabetes occurs when the islets are unable to sustain β cell compensation in the presence of insulin resistance. Weight loss often improves islet β cell function in association with reductions in insulin resistance [31, 32]. However, the islet β cell failure may be progressive and, therefore, not recoverable, particularly after hyperglycemia is established, which leads to poorly functioning, de-differentiated β cells, and a loss of β cell mass from apoptosis [33]. Preclinical studies provide strong evidence that exenatide plays an important role in the maintenance of β cell mass and function by increasing the expression of key β cell genes, stimulating islet cell proliferation and neogenesis, and inhibiting islet cell apoptosis [13]. However, human β cells appear to be much less responsive to proliferative agents such as GLP-1 compared to rodent β cells [34], and β cell replication is substantially diminished in older human subjects [35]. This may explain the changes observed in the HOMA- β values in the patient, which indicated that the ability to secrete insulin was not

recovered following exenatide treatment and concurrent weight loss.

Peptide YY_{3–36} [36], leptin [37–40], resistin [6], and ghrelin [41] are the hormones that modulate appetite and affect food intake. The levels of these hormones were not measured; however, they may contribute to understanding the extreme weight loss by exenatide in the patient.

A previous study [42] demonstrated that 1 year of exenatide treatment significantly improved β cell function and decreased body weight in the presence of similar improvements in glycemic control, when compared with insulin glargine treatment. However, after cessation of the exenatide therapy, these beneficial effects were not sustained, suggesting that ongoing treatment is necessary for exenatide to be effective. Similarly, in the present study, the patient's appetite recovered after ceasing exenatide treatment, and she regained 3 kg within the following 2 months.

The treatment with another type of GLP-1 receptor agonist, liraglutide, led to weight loss in overweight or obese patients with or without type 2 diabetes [43–47]. In addition, the current phase 3, randomized, controlled trial demonstrates the efficacy of liraglutide 3.0 mg per day, combined with lifestyle modification, in facilitating the maintenance of clinically meaningful weight loss; thus, liraglutide holds promise as an anti-obesity drug [48]. Moreover, a once-weekly formulation of exenatide was developed recently, and patients treated with once-weekly exenatide showed better glycemic control with sustained overall weight loss than patients treated with insulin glargine [49, 50]. Therefore, these drugs can be an alternative option for patients such as the one described in this case report.

In conclusion, 1 year of exenatide treatment was effective for reducing body weight and

improving glycemic control in a 59-year-old morbidly obese woman with type 2 diabetes. At the same time, her insulin sensitivity recovered but the ability to secrete insulin did not recover. After 1 year of exenatide treatment, decreased glucagon, active GLP-1, and total GIP levels were observed following a meal, suggesting that exenatide might affect these hormonal reactions.

ACKNOWLEDGMENTS

Sponsorship for this study was funded by the Joint Research Association for Japanese Diabetes. Dr. Miyako Kishimoto is the guarantor for this article, and takes responsibility for the integrity of the work as a whole.

Conflict of interest. Miyako Kishimoto declares that she has no conflict of interest. Mitsuhiro Noda has received speaker honorarium from Drug Company Astrazeneca.

Compliance with ethics guidelines. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from the patient for being included in the study.

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

REFERENCES

1. World Health Organization. Obesity and overweight. <http://www.who.int/mediacentre/factsheets/fs311/en/> (accessed 13 January 2014).
2. Goto M, Morita A, Goto A, SCOP Study Group, et al. Reduction in adiposity, β -cell function, insulin sensitivity, and cardiovascular risk factors: a prospective study among Japanese with obesity. *PLoS ONE*. 2013;8:e57964.
3. Wing RR, Lang W, Wadden TA, Look AHEAD Research Group, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes Care*. 2011;34:1481–6.
4. Matsushita Y, Nakagawa T, Yamamoto S, et al. Effect of longitudinal changes in visceral fat area and other anthropometric indices to the changes in metabolic risk factors in Japanese men: the Hitachi Health Study. *Diabetes Care*. 2012;35:1139–43.
5. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science*. 1993;259:87–91.
6. Stepan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. *Nature*. 2001;409:307–12.
7. Harayama T, Yoshida T, Yoshioka K, et al. Correlation between weight loss and improvement of diabetes mellitus among obese type 2 diabetic patients. *Diabetol Int*. 2013;4:132–7.
8. Drucker DJ. The biology of incretin hormones. *Cell Metab*. 2006;3:153–65.
9. Drucker DJ. Incretin-based therapy and the quest for sustained improvements in β -cell health. *Diabetes Care*. 2011;34:2133–5.
10. Holst JJ, Deacon CF. Is there a place for incretin therapies in obesity and prediabetes? *Trends Endocrinol Metab*. 2013;24:145–52.
11. Deane AM, Nguyen NQ, Stevens JE, et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. *J Clin Endocrinol Metab*. 2010;95:215–21.
12. Vrang N, Larsen PJ. Proglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. *Prog Neurobiol*. 2010;92:442–62.
13. Barnett AH. New treatments in type 2 diabetes: a focus on the incretin-based therapies. *Clin Endocrinol*. 2009;70:343–53.
14. Vilsbøll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. *J Clin Endocrinol Metab*. 2003;88:2706–13.
15. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. *Diabetes Care*. 2010;33:1173–5.
16. Unger JR, Parkin CG. Glucagon-like peptide-1 (GLP-1) receptor agonists: differentiating the new medications. *Diabetes Ther*. 2011;2:29–39.
17. Buse JB, Rosenstock J, Sesti G, LEAD-6 Study Group, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet*. 2009;374:39–47.
18. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in overweight metformin-treated patients with type 2 diabetes mellitus. *Diabetes Obes Metab*. 2006;8:419–28.
19. Mathieu C, Ostenson CG, Matthaei S, et al. Using exenatide twice daily or insulin in clinical practice: results from CHOICE. *Diabetes Ther*. 2013;4:285–308.
20. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. *Diabetes Obes Metab*. 2006;8:436–47.
21. Al-Jebawi AF. Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment. *Diabetes Res Clin Pract*. 2010;90:e88–90.
22. Buysschaert M, Preumont V, Oriot PR, UCL Study Group for Exenatide, et al. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. *Diabetes Metab*. 2010;36:381–8.
23. Bradley DP, Kulstad R, Schoeller DA. Exenatide and weight loss. *Nutrition*. 2010;26:243–9.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. 1985;28:412–9.

25. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. *Diabetes Care*. 2004;27:1487–95.
26. Quon MJ. QUICKI is a useful and accurate index of insulin sensitivity. *J Clin Endocrinol Metab*. 2002;87:949–51.
27. Holst JJ. The physiology of glucagon-like peptide 1. *Physiol Rev*. 2007;87:1409–39.
28. Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Holst JJ, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety—effect of obesity and weight reduction. *Int J Obes Relat Metab Disord*. 2001;25:1206–14.
29. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. *Diabetes*. 2008;57:1340–8.
30. Ghazi T, Rink L, Sherr JL, Herold KC. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and IV glucose challenges. *Diabetes Care*. 2014;37:210–6.
31. Gumbiner B, Polonsky KS, Beltz WF, et al. Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus. *J Clin Endocrinol Metab*. 1990;70:1594–602.
32. Villareal DT, Banks MR, Patterson BW, Polonsky KS, Klein S. Weight loss therapy improves pancreatic endocrine function in obese older adults. *Obesity*. 2008;16:1349–54.
33. Prentki M, Nolan CJ. Islet β cell failure in type 2 diabetes. *J Clin Invest*. 2006;116:1802–12.
34. Parnaud G, Bosco D, Berney T, et al. Proliferation of sorted human and rat beta cells. *Diabetologia*. 2008;51:91–100.
35. Perl S, Kushner JA, Buchholz BA, et al. Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. *J Clin Endocrinol Metab*. 2010;95:E234–9.
36. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. *N Engl J Med*. 2003;349:941–8.
37. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. *Nature*. 1998;395:763–70.
38. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. *Science*. 1995;269:540–3.
39. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. *Science*. 1995;269:543–6.
40. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. *Science*. 1995;269:546–9.
41. Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. *Neuron*. 2003;37:649–61.
42. Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. *Diabetes Care*. 2009;32:762–8.
43. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. *BMJ*. 2012;344:d7771.
44. Ottney A. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes. *Am J Health Syst Pharm*. 2013;70:2097–103.
45. Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. *Diabetes Obes Metab*. 2009;11:1163–72.
46. Niswender K, Pi-Sunyer X, Buse J, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. *Diabetes Obes Metab*. 2013;15:42–54.
47. Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. *Diabetes Res Clin Pract*. 2012;97:258–66.
48. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. *Int J Obes*. 2013;37:1443–51.

-
49. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *Lancet*. 2010;375:2234–43.
 50. Diamant M, Van Gaal L, Stranks S, et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. *Diabetes Care*. 2012;35:683–9.